{"nctId":"NCT04541004","briefTitle":"Adolescent Mite Allergy Safety Evaluation","startDateStruct":{"date":"2020-09-23","type":"ACTUAL"},"conditions":["Allergic Rhinitis","Allergic Rhinoconjunctivitis"],"count":253,"armGroups":[{"label":"HDM SLIT Tablet","type":"EXPERIMENTAL","interventionNames":["Biological: HDM SLIT-tablet"]}],"interventions":[{"name":"HDM SLIT-tablet","otherNames":["ACARIZAX, ODACTRA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent\n* Male or female subjects aged ≥12 to ≤17 years\n* A clinical history of allergic rhinitis/rhinoconjunctivitis (AR/C) when exposed to HDM\n* Positive skin prick test (SPT) to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae at screening\n* Lung function measured by Forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted value or according to local requirements while on subject's usual asthma medication\n* The subject must be willing and able to comply with trial protocol and adhere to IMP treatment\n\nMain Exclusion Criteria:\n\n* A subject who has previously been included in studies with the HDM SLIT-tablet, or otherwise being treated with the marketed HDM SLIT-tablet (e.g. ACARIZAX, ODACTRA)\n* Any SLIT or SCIT treatment with D. pteronyssinus or D. farinae reaching the maintenance dose within the last 5 years. In addition, any SLIT or SCIT treatment with D. pteronyssinus or D. farinae within the previous 12 months prior to visit 1\n* Ongoing treatment with any allergy immunotherapy product at screening\n* Severe chronic oral inflammation\n* A diagnosis or history of eosinophilic oesophagitis\n* Any clinical deterioration of asthma that resulted in emergency treatment, hospitalisation or treatment with systemic corticosteroids within 3 months prior to first tablet administration\n* Female with positive urine pregnancy test, breastfeeding, pregnant or planning to become pregnant within the projected duration of the trial\n* Sexually active female of childbearing potential without medically accepted contraceptive method","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE)","description":"At least one TEAE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects With at Least One Treatment-emergent Adverse Event (TEAE)","description":"At least one TEAE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Treatment-emergent Adverse Events (TEAEs)","description":"At least one TEAE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1940","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With at Least One Solicited Treatment-emergent Adverse Event (TEAE)","description":"At least one solicited TEAE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"216","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With at Least One Solicited Treatment-emergent Adverse Event (TEAE)","description":"At least one solicited TEAE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Solicited Treatment-emergent Adverse Events (TEAEs)","description":"At least one solicited TEAE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1796","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With at Least One IMP-related Adverse Event (AE)","description":"At least one IMP-related AE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With at Least One IMP-related Adverse Event (AE)","description":"At least one IMP-related AE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of IMP-related Adverse Events (AEs)","description":"At least one IMP-related AE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1863","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With At Least One Treatment-emergent Serious Adverse Event (SAE)","description":"At least one treatment-emergent SAE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With At Least One Treatment-emergent Serious Adverse Event (SAE)","description":"At least one treatment-emergent SAE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent Serious Adverse Events (SAEs)","description":"At least one treatment-emergent SAE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":253},"commonTop":["Oral pruritus","Throat irritation","Ear pruritus","Tongue ulceration","Glossodynia"]}}}